Stryker Co. (NYSE:SYK) Shares Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH raised its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 7.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 102,290 shares of the medical technology company's stock after purchasing an additional 7,339 shares during the period. Erste Asset Management GmbH's holdings in Stryker were worth $37,602,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Achmea Investment Management B.V. grew its holdings in Stryker by 5.0% during the fourth quarter. Achmea Investment Management B.V. now owns 35,362 shares of the medical technology company's stock valued at $12,733,000 after purchasing an additional 1,672 shares during the period. Mascoma Wealth Management LLC boosted its stake in shares of Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after acquiring an additional 27 shares during the period. Rakuten Securities Inc. boosted its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the period. Avantax Advisory Services Inc. boosted its stake in shares of Stryker by 4.4% in the fourth quarter. Avantax Advisory Services Inc. now owns 21,273 shares of the medical technology company's stock worth $7,659,000 after acquiring an additional 887 shares during the period. Finally, Essential Planning LLC. bought a new position in shares of Stryker in the fourth quarter worth about $1,354,000. Institutional investors own 77.09% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Morgan Stanley raised Stryker from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. JPMorgan Chase & Co. boosted their target price on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research report on Thursday, January 30th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus boosted their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $421.90.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Stock Down 0.0 %

Shares of SYK stock traded down $0.05 on Thursday, reaching $363.79. 1,965,827 shares of the stock were exchanged, compared to its average volume of 1,221,728. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business's 50 day moving average price is $382.87 and its 200 day moving average price is $373.26. The company has a market capitalization of $138.81 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm earned $3.46 earnings per share. As a group, sell-side analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker's dividend payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.